Production (Stage)
NLS Pharmaceutics AG
NLSP
$2.30
$0.2210.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.21M | 3.86M | 4.52M | 5.21M | 5.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.64M | 4.97M | 6.31M | 9.06M | 11.81M |
| Operating Income | -3.64M | -4.97M | -6.31M | -9.06M | -11.81M |
| Income Before Tax | -1.98M | -4.29M | -6.60M | -9.38M | -12.17M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.98 | -4.29 | -6.60 | -9.38 | -12.17 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.98M | -4.29M | -6.60M | -9.38M | -12.17M |
| EBIT | -3.64M | -4.97M | -6.31M | -9.06M | -11.81M |
| EBITDA | -3.63M | -4.96M | -6.30M | -9.05M | -11.80M |
| EPS Basic | -2.93 | -4.83 | -6.72 | -9.74 | -12.75 |
| Normalized Basic EPS | -1.74 | -2.97 | -4.20 | -6.09 | -7.97 |
| EPS Diluted | -2.93 | -4.83 | -6.72 | -9.74 | -12.75 |
| Normalized Diluted EPS | -1.74 | -2.97 | -4.20 | -6.09 | -7.97 |
| Average Basic Shares Outstanding | 6.17M | 5.09M | 4.01M | 3.91M | 3.82M |
| Average Diluted Shares Outstanding | 6.17M | 5.09M | 4.01M | 3.91M | 3.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |